Related Experiment Videos
Topiramate in opiate withdrawal
Daniele F Zullino1, Anne-Claude Cottier, Jacques Besson
1Division of Substance Abuse, University Department of Adult Psychiatry, Prilly-Lausanne, Switzerland. Daniele.Zullino@inst.hospvd.ch
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|November 28, 2002
Summary
Topiramate shows promise in managing opiate withdrawal symptoms, offering a potential alternative to clonidine. This study suggests topiramate effectively controlled withdrawal symptoms in three patients undergoing detoxification.
Area of Science:
- Neuroscience
- Pharmacology
- Addiction Medicine
Background:
- Clonidine, an alpha2-adrenergic agonist, is the primary medication for opiate withdrawal but has suboptimal efficacy and tolerance.
- Opiate withdrawal involves the activation of the locus coeruleus (LC) by glutamate, leading to significant symptoms.
Observation:
- Topiramate's pharmacological profile suggests potential utility in opiate withdrawal treatment.
- Topiramate is known to inhibit alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, which are implicated in LC activation during withdrawal.
Findings:
- Three patients undergoing inpatient opiate detoxification were treated with topiramate.
- Topiramate administration resulted in nearly complete control of opiate withdrawal symptoms in the observed patients.
Implications:
- Topiramate may represent a valuable therapeutic option for managing opiate withdrawal.
- Further research into topiramate's efficacy and safety for opiate detoxification is warranted.
- Targeting AMPA receptors could be a key mechanism in mitigating withdrawal symptoms.